InsiderTrades.com logo
Mike Mensinger net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Mike Mensinger Biography and Net Worth

Insider of Beta Bionics

Mike Mensinger’s role as Chief Product Officer is to drive the strategic direction and execution of the product portfolio for Beta Bionics.  As the previous co-founder and Chief Technology Officer at Companion Medical (acquired by Medtronic), Mike was responsible for R&D and Manufacturing and launched the InPen system – the first and only FDA-cleared smart insulin pen paired with an integrated diabetes management app. Prior to Companion Medical, Mike was an early employee at Dexcom and helped drive the software engineering team, mobile apps and larger R&D programs.  Mike earned a Bachelor of Computer Engineering degree in computer software engineering from University of Delaware.

What is Mike Mensinger's net worth?

The estimated net worth of Mike Mensinger is at least $2.79 million as of September 2nd, 2025. Mensinger owns 91,815 shares of Beta Bionics stock worth more than $2,789,340 as of December 4th. This net worth estimate does not reflect any other investments that Mensinger may own. Learn More about Mike Mensinger's net worth.

How do I contact Mike Mensinger?

The corporate mailing address for Mensinger and other Beta Bionics executives is 11 HUGHES, IRVINE, CA, 92618. Beta Bionics can also be reached via phone at (949) 427-7785 and via email at [email protected]. Learn More on Mike Mensinger's contact information.

Has Mike Mensinger been buying or selling shares of Beta Bionics?

Mike Mensinger has not been actively trading shares of Beta Bionics within the last three months. Most recently, Mike Mensinger sold 1,089 shares of the business's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $18.86, for a transaction totalling $20,538.54. Following the completion of the sale, the insider now directly owns 91,815 shares of the company's stock, valued at $1,731,630.90. Learn More on Mike Mensinger's trading history.

Who are Beta Bionics' active insiders?

Beta Bionics' insider roster includes Stephen Feider (CFO), Mark Hopman (Insider), Mike Mensinger (Insider), and Steven Russell (Insider). Learn More on Beta Bionics' active insiders.

Are insiders buying or selling shares of Beta Bionics?

In the last twelve months, Beta Bionics insiders bought shares 2 times. They purchased a total of 1,033,350 shares worth more than $17,566,950.00. In the last twelve months, insiders at the sold shares 18 times. They sold a total of 76,232 shares worth more than $1,471,002.63. The most recent insider tranaction occured on October, 31st when Director Adam Lezack sold 1,406 shares worth more than $37,779.22. Learn More about insider trades at Beta Bionics.

Information on this page was last updated on 10/31/2025.

Mike Mensinger Insider Trading History at Beta Bionics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/2/2025Sell1,063$29.34$31,188.4290,752View SEC Filing Icon  
9/2/2025Sell1,089$18.86$20,538.5491,815View SEC Filing Icon  
6/2/2025Sell1,115$17.89$19,947.3592,904View SEC Filing Icon  
1/31/2025Buy33,350$17.00$566,950.0059,019View SEC Filing Icon  
See Full Table

Mike Mensinger Buying and Selling Activity at Beta Bionics

This chart shows Mike Mensinger's buying and selling at Beta Bionics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Beta Bionics Company Overview

Beta Bionics logo
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Read More

Today's Range

Now: $30.00
Low: $29.56
High: $31.51

50 Day Range

MA: $25.15
Low: $19.53
High: $31.51

2 Week Range

Now: $30.00
Low: $8.89
High: $32.71

Volume

2,652,084 shs

Average Volume

474,329 shs

Market Capitalization

$1.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A